A new breast cancer drug which extends women's lives by almost six months could be blocked from routine NHS access because it is too expensive, a health watchdog says.
Kadcyla, manufactured by Roche, can cost more than £90,000 per patient and is not effective enough to justify the price the NHS is being asked to pay, the National Institute for Health and Care Excellence (Nice) said.
The watchdog, which decides which new medicines are cost effective, said its guidance for the drug, also known as trastuzumab emtansine, was in draft form and is now up for public consultation.
If the recommendations are adopted, patients would have to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug, a Nice spokeswoman said.
More top news
Tiny New Zealand town with too many vacant jobs and affordable homes received 10,000 messages globally after putting out a call.
Commuters have been stopped in their tracks at the moving sight of hundreds of actors in First World War uniform up and down the country.
The Constitutional Court's ruling will give defeated far-right presidential hopeful Norbert Hofer another chance to be head of state.